ResearcherPeking University First HospitalActive in the last 2 years

Xiaoxue Pan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-9074-7303; OpenAlex author ID A5113164006. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper

Papers 1

SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113713 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xin Wang · 1 shared paper, 2025 · strength 0.26
- Paper SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. DOI 10.1016/j.isci.2025.113713 ↗
Shan-Wen Chen · 1 shared paper, 2025 · strength 0.26
- Paper SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. DOI 10.1016/j.isci.2025.113713 ↗
Xiaodong Tian · 1 shared paper, 2025 · strength 0.26
- Paper SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. DOI 10.1016/j.isci.2025.113713 ↗
Yinmo Yang · 1 shared paper, 2025 · strength 0.26
- Paper SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. DOI 10.1016/j.isci.2025.113713 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.